MagnetisMM-3: elranatamab for myeloma

(3:16)

Elranatamab for R/R myeloma: long-term updates from MagnetisMM-3 \u0026 real-world safety of this agent

(6:7)

Multiple myeloma: elranatamab as a single-agent therapy compared to CAR-T therapy

(2:12)

Elranatamab Induces Durable Responses for Patients with Relapsed or Refractory Multiple Myeloma

(7:)

Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma

(1:52)

MagnetisMM-3: elranatamab in R/R multiple myeloma naive to BCMA-directed therapy

(6:7)

MagnestisMM-1: elranatamab alone or with immunomodulatory agents in R/R multiple myeloma

(2:47)

Patient-reported outcomes with the use of elranatamab in the MagnetisMM-3 trial

(3:27)

What Does MagentisMM-3 Data Tell Us About Elranatamab?

(9:44)

The promise of elranatamab and other bispecifics in the treatment of myeloma

(1:37)

All about ELREXFIO (elranatamab)

(27:16)

Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.

(56:35)

MagnetisMM-4: elranatamab in combination with other agents for patients with multiple myeloma

(2:10)

Elranatamab - Upcoming Myeloma Therapy

(15:43)

MagnetisMM-1: investigating the efficacy of elranatamab in patients with R/R multiple myeloma

(2:12)

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma

(2:)

Evaluating the safety and efficacy of elranatamab in multiple myeloma

(4:17)

Myeloma: elranatamab mechanism of action

(1:46)

Efficacy and Safety of Elranatamab in Pts with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3

(9:14)

The safety and efficacy of elranatamab in patients with R/R AL amyloidosis

(55)